Hemera Biosciences was founded with the sole mission of preserving vision using gene therapy in our patients with age-related macular degeneration (AMD). As physicians and scientists, we have been frustrated by our inability to provide treatment for our patients with macular degeneration. We embarked on this mission to preserve vision by developing a gene therapy called HMR59.
Currently, HMR59 is under FDA clinical trial testing as a one-time treatment for both the dry and wet forms of AMD. HMR59 is injected during a routine office visit with the goal of preserving vision that will endure the life of our patients.
What is HMR59?
HMR59 is Hemera’s one-time gene therapy treatment given in a retina specialist’s office. This drug is currently being evaluated in FDA approved clinical trials to treat both dry and wet age-related macular degeneration (AMD). Macular degeneration is felt to be caused by an overactivity of an inflammation cascade called complement. HMR59 works by causing retina cells to continuously produce a soluble protein called CD59 (sCD59) that blocks the final step of the complement cascade.